Virpax Pharmaceuticals Reports 2022 Third Quarter Results
–Company Highlights Development Timelines for Product Candidates– BERWYN, Pa.–(BUSINESS WIRE)–#earnings–Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) a company specializing in developing non-addictive product candidates for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the quarter ended September 30, 2022, and other recent … [Read more…]
